Marimed Inc (MRMD) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Marimed Inc stock $0.05, price $0.05, upside -2.1%, quality 33 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
60‑month range $0.0507 – $1.02 · fair‑value band $0.0364 – $0.0810 · the $0.0530 price screens above the $0.0519 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Marimed in your weekly email
Every Wednesday you see whether Marimed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States.
Show moreShow less
The company sells cannabis flower, vapes, and concentrates under the Nature's Heritage brand; and cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty's Eddies brand.
It offers soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under InHouse brand. The company licenses its brands.
MariMed Inc. was incorporated in 2011 and is headquartered in Norwood, Massachusetts.
Stock analysis
Marimed Inc (MRMD) currently trades at $0.0530, while our model-based Fair Value estimate is $0.0519, so the stock looks roughly fairly valued today (gap 2.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.4000 per share, and 8 of the 10 models we run sit above the $0.0530 price.
Bear case: the Asset-Based group reads lowest at $0.0100, and 2 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: $0.0364 (bear) to $0.0810 (bull), the price of $0.0530 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Marimed Inc reported revenue of $160M in FY2025 versus $121M in FY2021, a compound +7.1%/yr. Reported net income was −$14.5M in FY2025.
Key figures
Market cap $21.1M Micro · P/S ratio 0.13 · EPS (TTM) $−0.0400 · Dividend yield 0.6% · Net margin −9.1% · Return on equity −24.2% · Return on assets (EBIT) 8.8% · Operating margin 1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −2%, MRMD screens cheaper than that median.
Fair Value models
Bear$0.0364Fair Value $0.0519Bull$0.0810
Price $0.0530 · Upside -2.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.7%
Start year 2020 (pandemic). Over 10 years: +62.2% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+97.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
28.6% (2020) → −0.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 577 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−2.1% · Above median
Profitability
Return on assets−7.2% · Bottom 25%
Net margin (12 months)−9.1% · Bottom 25%
Operating margin (12 months)1.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)6.1% · Above median
Dividend yield (12 months)0.6% · Bottom 25%
Balance sheet
Debt / equity1.40× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Marimed Inc Fair Value". https://www.fairvalue-calculator.com/stock/MRMD
Frequently asked questions
Is Marimed Inc (MRMD) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $0.0519 versus a price of $0.0530, about −2% upside (fairly valued).
What is the fair value of MRMD?
Our model-based fair value for Marimed Inc is $0.0519 (as of Oct 29, 2026), built from audited fundamentals. The current price: $0.0530.
What is the quality score of MRMD?
Marimed Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Marimed Inc (MRMD)?
Our model-based price target is the fair value of $0.0519 (as of Oct 29, 2026) from 10 valuation models. Cautious scenario $0.0364, optimistic scenario $0.0810. It is a calculation from audited fundamentals, not an analyst target.
What is the Marimed Inc stock forecast for 2026?
Our models put fair value at $0.0519, about −2% upside versus a price of $0.0530 (fairly valued). Cautious scenario $0.0364, optimistic scenario $0.0810. The calculation is refreshed regularly with new filings.
What is the revenue of Marimed Inc (MRMD)?
Marimed Inc reported trailing-twelve-month revenue of about $164M (latest available figure, as of Oct 29, 2026).
Does Marimed Inc pay a dividend?
Marimed Inc currently shows a dividend yield of 0.63% relative to its recent price (as of Oct 29, 2026).
What growth is priced into Marimed Inc (MRMD)?
For today's price to be fair in a discounted-cash-flow model, Marimed Inc would have to grow free cash flow by +5.1 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.7 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of MRMD use?
Our models discount Marimed Inc at 10.7 %: a base by market capitalisation (nano), damped by beta 1.40, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Marimed Inc that is +5.1 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Marimed Inc (MRMD) delivered so far?
Over the past 5 years revenue at Marimed Inc grew +25.7 % a year. The price currently implies +5.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Marimed Inc (MRMD) growing?
The median revenue growth in the sector is +6.0 % a year. That is the yardstick for the growth priced into Marimed Inc (+5.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Marimed Inc (MRMD)?
The free-cash-flow yield on the price is 28.78 %: that much free cash flow Marimed Inc produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Marimed Inc (MRMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Marimed Inc it is $0.0519 per share (as of Oct 29, 2026), against a price of $0.0530. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Marimed Inc stock overvalued or undervalued in 2026?
As of Oct 29, 2026, MRMD trades above its calculated fair value: price $0.0530, fair value $0.0519, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MRMD?
No. The price is what the market pays today ($0.0530); the fair value is what the company's own numbers justify ($0.0519). For Marimed Inc the two are $0.0011 per share apart. That gap is exactly why we show both numbers side by side.
How much is Marimed Inc worth?
The market values Marimed Inc at about $21.1M (market capitalisation, as of Oct 29, 2026). Per share that is $0.0530; our models calculate a fair value of $0.0519 per share.
What do the bullish and bearish scenarios say about MRMD?
Our models span a range for Marimed Inc: cautious scenario $0.0364, base $0.0519, optimistic $0.0810 per share (as of Oct 29, 2026, price $0.0530). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Marimed Inc (MRMD)?
Balance-sheet figures for Marimed Inc (as of Oct 29, 2026): return on equity −24.2%, debt of 1.40 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is MRMD from its 52-week high?
Marimed Inc trades at $0.0530, about 63% below its 52-week high of $0.1440 and 5% above the low of $0.0507 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0519 is for.
Which stocks are comparable to Marimed Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Marimed Inc stock attractive at the current price?
The data as of Oct 29, 2026: price $0.0530, calculated fair value $0.0519 (−2%), Quality Score 33/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MRMD calculated?
We run Marimed Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0519, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Marimed Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Marimed Inc (MRMD)?
The closing price on Oct 29, 2026 was $0.0530. Our model-based fair value is $0.0519, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Marimed Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.0364 to $0.0810) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Marimed Inc
How large is the market capitalisation of Marimed Inc (MRMD)?
The market capitalisation of Marimed Inc is $21.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Marimed Inc (MRMD)?
The price-to-sales ratio of Marimed Inc is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Marimed Inc (MRMD)?
Earnings per share at Marimed Inc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Marimed Inc (MRMD)?
The dividend yield of Marimed Inc is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Marimed Inc (MRMD)?
The net margin of Marimed Inc is −9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Marimed Inc (MRMD)?
The return on equity (ROE) of Marimed Inc is −24.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Marimed Inc (MRMD)?
On an EBIT basis the return on assets of Marimed Inc is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Marimed Inc (MRMD)?
The operating margin of Marimed Inc is 1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Marimed Inc (MRMD)?
Revenue at Marimed Inc is growing +6.1% versus a year earlier (3y avg +6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Marimed Inc (MRMD)?
Earnings per share at Marimed Inc are growing +30.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Marimed Inc (MRMD) carry?
The net debt of Marimed Inc is $63.9M (fiscal year 2025, ≈ 10.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Marimed Inc in the live analysis
One click puts Marimed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 29, 2026